Dave Mori

Chief Business Officer
Member, Board of Directors

Dave Mori is an accomplished entrepreneur with more than 20 years of experience operating and advising businesses, including 15 start-up companies, in Canada, Japan, and the United States. As chief business officer, Dave leads Nonagen Bioscience’s planning, strategy, and business development. He is passionate about helping organizations that prevent and cure cancer. Dave earned a bachelor of commerce degree in entrepreneurial management from Royal Roads University in British Columbia, Canada.

Mary Pietryga, MBA

Chief Commercial Officer

Mary Pietryga is an experienced and creative business executive with a diversified background in the pharmaceutical/bioscience and medical device industry. Her career spans commercial sales, payer access and pricing, and strategic marketing. This unique background has enabled her to develop and lead the execution of multiple successful product launches and brand growth strategies. In addition to serving as Nonagen Bioscience’s chief commercial officer, Mary is a partner at Peregrine Market Access. Previously, she held senior officer roles at midsized and major Fortune 500 companies such as Sanofi and Teva Pharmaceuticals, among other commercial corporate leadership positions domestically and abroad. 

Steve J. Hodges, MD

Member, Board of Directors

Dr. Steven Hodges is a practicing urologist and an associate professor of urology at Wake Forest University School of Medicine. He has founded 3 companies (Applied Catheter Technologies, Inc; Sneez; and Akesian Health Sciences, Inc). He earned a bachelor’s degree from Duke University and a medical degree from Wake Forest University School of Medicine (Bowman Gray Medical School), where he completed his residency. Subsequently, he completed a fellowship at University of California San Diego. 

Wayne Hogrefe, PhD

Interim Chief Operating Officer
Member, Board of Directors

Dr. Wayne Hogrefe has more than 30 years of experience in the diagnostics industry, including research and assay development for vaccine responses, vector-borne diseases, viral pathogens, and emerging pathogens. Dr. Hogrefe holds several patents and has had more than 30 peer-reviewed articles published. He has held leadership positions at Q2 Solutions, St. Luke’s Hospital in Cleveland, Ohio, Focus Diagnostics, and Quest Diagnostics. Dr. Hogrefe is an emeritus diplomate of the American Board of Medical Laboratory Immunology.

Peter Black, MD

Scientific Advisor

Dr. Peter Black is the senior research scientist and associate director of clinical research at the Vancouver Prostate Centre and a professor in the department of urologic sciences at the University of British Columbia. Dr. Black’s clinical subspecialty interest is in the treatment of urologic cancers, especially bladder and prostate cancer. Dr. Black is an active clinical trialist and an ad hoc journal reviewer for more than 30 journals, receiving numerous awards for peer review. He has had more than 315 peer-reviewed articles published. Dr. Black is the founding editor-in-chief of the Society Internationale d’Urologie Journal. He is also general secretary of the International Bladder Cancer Network.  

Chi Fai Ng, MD, FRCSEd, FHKAM

Scientific Advisor

Dr. Chi Fai Ng is a surgeon with research interests in stone diseases and prostate diseases. He has had more than 200 peer-reviewed articles published and written nearly 20 book chapters. He is a professor at The Chinese University of Hong Kong in the division of urology and department of surgery. Dr. Ng has led his team to revolutionize the diagnostic approach and management of urologic cancers in the territory. He holds the distinction of being the first surgeon in Asia to perform a robotic prostatectomy using the da Vinci SP® system. Dr. Ng founded the Asian Urological Surgery Training and Educational Group to train the next generation of urologists in Asia. 

Juan Palou Redorta, MD, PhD, FEBU, FRCS

Scientific Advisor

Dr. Juan Redorta is a renowned urologist who specializes in urological oncology. He is the chair of the urology department at Fundació Puigvert and a professor of urology at the Universitat Autònoma de Barcelona in Barcelona, Spain. Dr. Redorta is the chair of the European School of Urology. His main interests are clinical research in oncology (mainly urothelial cell carcinomas, especially non-muscle-invasive bladder cancer and upper urinary tract tumors), laparoscopy, and robotic surgery. Dr. Redorta is a member of the group that oversees the development of the European Association of Urology Guidelines for non-muscle-invasive bladder cancer and upper urinary tract tumors. He is a sought-after lecturer at national and international meetings and at university hospitals around the world. 

Wei Yang, PhD

Scientific Advisor

Dr. Wei Yang is currently an associate professor of surgery and biomedical sciences at Cedars-Sinai Medical Center, where he also previously served as the director of the Mass Spectrometry and Biomarker Discovery Core. In addition to his work at Cedars-Sinai Medical Center, Dr. Yang serves as an associate professor of medicine at the University of California. His research focuses on developing and applying leading-edge proteomics technologies to identify novel cancer biomarkers and clinically actionable anti-cancer drug targets as well as their mechanisms of action. Dr. Yang’s research is funded by the National Cancer Institute (NCI) and the Department of Defense (DoD). He is a reviewer for over 30 prestigious scientific journals such as Nature Communications and Theranostics. 

Zhen Zhang, PhD, FRCSEd

Scientific Advisor

Dr. Zhen Zhang is an associate director of the Center for Biomarker Discovery and Translation and an associate professor of pathology and oncology at Johns Hopkins University School of Medicine. Currently, Dr. Zhang’s research is focused on the design of large-scale discovery studies for biomarkers and other molecular targets and their translation into clinical applications. Dr. Zhang is a principal investigator at the National Cancer Institute (NCI)-funded Clinical Proteomic Tumor Analysis Consortium Center at Johns Hopkins University and the contact principal investigator of the NCI’s Early Detection Research Network Biomarker Development Laboratory. He designed and conducted a large-scale multicenter discovery study and successfully applied these algorithms and tools to the generated proteomic data, discovering/validating a panel of biomarkers. He then derived a classification algorithm using these biomarkers as part of its input. The result, produced with his colleague Daniel Chan, became the first in vitro diagnostic multivariate index assay (IVDMIA) of proteomic biomarkers ever cleared by the FDA for clinical use.